Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)
China flag China · Delayed Price · Currency is CNY
8.88
+0.17 (1.95%)
Nov 6, 2026, 3:00 PM CST

SHA:603707 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
-1,3951,0241,2101,389658.55
Trading Asset Securities
-1,3171,055681.991.3259.8
Cash & Short-Term Investments
3,4382,7112,0801,8921,390918.35
Cash Growth
27.38%30.35%9.94%36.12%51.34%-31.43%
Accounts Receivable
-1,229920.04771.68974.11897.75
Other Receivables
-235.35273.46230.88241.94167.88
Receivables
-1,4651,1941,0031,2161,066
Inventory
-3,2653,6754,1585,6164,894
Prepaid Expenses
-13.113.1711.988.467.98
Other Current Assets
-66.3284.42196.9964.1443.62
Total Current Assets
-7,5207,0467,2628,2946,930
Property, Plant & Equipment
-1,1921,1971,2351,198827.42
Long-Term Investments
-92.0883.2672.4861.626.39
Goodwill
-126.64129.51127.61125.48114.87
Other Intangible Assets
-410.37337.53174.1118.96123.85
Long-Term Deferred Tax Assets
-136.07203.25348.4101.4734.54
Long-Term Deferred Charges
-774.46459.55294.2494.6277.65
Other Long-Term Assets
-90.6853.710.3816.3182.34
Total Assets
-10,3439,5109,52410,0108,217

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
-589.12495.66537.74505.12458.87
Accrued Expenses
-241.87207.11294.8588.1564.56
Short-Term Debt
-1,4261,2361,5671,9571,571
Current Portion of Long-Term Debt
-838.158.21505.450.42-
Current Portion of Leases
-4.83----
Current Income Taxes Payable
-26.443.7229.310.448.73
Current Unearned Revenue
-31.8359.0335.9338.2225.07
Other Current Liabilities
-46.2954.67116.18115.44138.56
Total Current Liabilities
-3,2052,0643,0862,7052,266
Long-Term Debt
-24.14824.16512.37997.36480.75
Long-Term Leases
-59.3510.2813.2315.94-
Long-Term Unearned Revenue
-104.8884.6376.5784.9965.51
Long-Term Deferred Tax Liabilities
-49.8638.2837.3339.991.42
Total Liabilities
-3,4433,0223,7263,8432,814

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
-1,6161,6161,6171,6171,244
Additional Paid-In Capital
-587.3587.29601.02603.59987.96
Retained Earnings
-4,6244,2043,5403,9153,123
Treasury Stock
--15.01--27.75-32.82-47.3
Comprehensive Income & Other
-90.8584.6272.567.970.45
Total Common Equity
6,9406,9036,4925,8026,1715,378
Minority Interest
--3.54-3.51-3.47-3.4724.84
Shareholders' Equity
6,9366,8996,4885,7986,1675,403
Total Liabilities & Equity
-10,3439,5109,52410,0108,217

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,5582,3532,0792,5982,9712,051
Net Cash (Debt)
880.63358.171.13-706.06-1,581-1,133
Net Cash Growth
220.67%31507.10%----
Net Cash Per Share
0.540.220.00-0.45-0.97-0.72
Filing Date Shares Outstanding
1,6941,6141,6161,4731,6531,543
Total Common Shares Outstanding
1,6941,6141,6161,4731,6531,543
Working Capital
-4,3154,9814,1755,5894,663
Book Value Per Share
4.234.284.023.943.733.49
Tangible Book Value
6,4486,3666,0255,5005,9265,139
Tangible Book Value Per Share
3.933.943.733.733.583.33
Buildings
-541.02472.9481.48448.47268.49
Machinery
-1,4831,3231,279981.72751.74
Construction In Progress
-4.72137.4479.74250.62215.26